Otonomy, Inc.: Series B $38.5M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Hearing Loss, X - Ménière's, X - Tinnitus, XX - CA

Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

Si-Bone, Inc.: Series B $10.6M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Device (Spine), XX - CA

Si-Bone (San Jose, CA) a commercial-stage medical device company focused on minimally-invasive approaches to sacroiliac joint disruptions and degenerative sacroiliitis, closed a $10.6M Series B. Participants include Skyline Ventures.

Health Market Science, Inc.: Series B $6.1M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - TeleMedicine, XX - PA

Health Market Science (King of Prussia, PA) a commercial-stage biopharma and healthcare data and analytics provider, closed a $6.1M Series B financing. Participants include Cross Atlantic Capital Partners and Edison Venture Fund.

Great Lakes Pharmaceuticals, Inc.: Series B $3.1M

Posted in I - Series B, Q - 3Q10, R - MID WEST, X - Antibacterial, X - Device (Catheter), X - Drug:Device Combo, XX - OH

Great Lakes Pharmaceuticals (Cleveland, OH) a clinical-stage drug:device company focused on catheter-related bloodstream infection, closed a $3.1M Series B financing. Participants include Charter Life Sciences, Early Stage Partners, Ohio Tech Angels and North Coast Angel Fund.

Dicerna Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - RNAi, XX - MA

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Nephera, Ltd.: Series B $2.8M

Posted in I - Series B, Q - 3Q10, R - INTERNATIONAL, X - Device (Cardiology), X - Device (Renal)

Nephera (Israel) a development-stage medical device company focused on kidney function in CHF patients, closed a $2.8M Series B financing. Participants include Aurum Ventures, Evergreen Venture Partners and Trendlines Group.

EndoStim, Inc.: Series B $6M

Posted in I - Series B, Q - 3Q10, R - SOUTH WEST, X - Device (GI), X - Device (Neuromuscular), X- GERD, XX - AZ

EndoStim (Phoenix, AZ) a development-stage medical device company focused on gastrointestinal and neuromuscular disorders, closed a $6M Series B financing. Participants include Santé Ventures, Prolog Ventures, Vectis Healthcare & Life Sciences Fund.

Pantech Biosolutions, AG: Series B $19M

Posted in I - Series B, Q - 3Q10, R - INTERNATIONAL, X - Device (Delivery)

Pantech Biosolutions (Liechtenstein) a clinical-stage device company focused on a laser-based transdermal delivery system for large-molecular weight drugs, closed a $19M Series B financing. Participants include StemCell Holding and Gamma Capital Partners.

Metamark Genetics, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, XX - MA

Metamark Genetics (Cambridge, MA) a development-stage molecular diagnostics company focused on prognostic assays for early-stage cancers, closed a $22M Series B financing. Participants may have included Perseus.

Trevena, Inc.: Series B $35M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Cardiology, X - G-Protein, X - Pain, XX - PA

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

« Previous Entries

to top of page...